Kallistatin is a potent new vasodilator

Area of Science:

• Physiology
• Pharmacology
• Cardiovascular Research

Background:

• Kallistatin is a serine proteinase inhibitor known to bind and inhibit tissue kallikrein.
• The direct effects of kallistatin on the vasculature and blood pressure homeostasis remain largely unexplored.
• Understanding kallistatin's vascular actions could reveal new therapeutic targets for hypertension.

Purpose of the Study:

• To investigate the direct impact of kallistatin on vascular function and blood pressure regulation.
• To elucidate the mechanism underlying kallistatin's hypotensive and vasodilatory effects.

Main Methods:

• Intravenous administration of human kallistatin in anesthetized rats to assess blood pressure changes.
• In vitro studies using isolated rat aortic rings and perfused rat kidneys to evaluate vasodilation.
• Pharmacological blockade with Hoe 140 (bradykinin B2-receptor antagonist) and N-nitro-L-arginine methyl ester (nitric oxide synthase inhibitor).
• Scatchard plot analysis to identify and characterize kallistatin-binding sites in rat aorta.

Main Results:

• Kallistatin induced a rapid, potent, and dose-dependent reduction in mean arterial blood pressure in rats.
• Kallistatin caused significant vasodilation in isolated aortic rings, both with and without endothelium, and in the renal vasculature.
• The vasodilatory and hypotensive effects of kallistatin were independent of bradykinin B2 receptors and nitric oxide pathways.
• Specific kallistatin-binding sites were identified in the rat aorta.

Conclusions:

• Kallistatin acts as a potent vasodilator, directly affecting vascular smooth muscle.
• Its blood pressure-lowering mechanism is independent of endothelial bradykinin receptors.
• Kallistatin represents a potential therapeutic agent for managing hypertension through direct vascular regulation.